文献速递前列腺癌

将前列腺多参数磁共振引入主动监测方案是否改善患者再分类?

Does the introduction of prostate multiparametric magnetic resonance imaging into the active surveillance protocol for localized prostate cancer improve patient re-classification?
PubMed 文献 · BJU Int · 2018-05-09

该研究纳入2010-2016年445例接受主动监测的低体积低至中危前列腺癌患者,比较引入mpMRI±靶向活检前后的再分类与治疗触发情况。结果发现mpMRI±靶向活检较单纯活检更易再分类并识别需治疗的患者,但两组至治疗时间无显著差异。

要点

  • mpMRI±靶向活检较单纯活检提高再分类率(44% vs 37%,P=0.003)。
  • 两组至治疗时间无显著差异(中位1.9 vs 1.33年,P=0.747)。
  • 最常见治疗触发为mpMRI及靶向活检后升级(29%)。

核心结论

  • 以mpMRI±靶向活检替代系统穿刺活检作为主动监测方案的一部分,可提高再分类可能性并识别需治疗的临床显著疾病患者。

研究设计与样本

  • 回顾性队列研究,纳入2010-2016年445例接受主动监测的低体积低至中危前列腺癌患者,中位随访2.4年(IQR 1.2-3.7)。
  • 按2014年前方案(含前列腺穿刺活检)与2014年后NICE指南方案(含mpMRI)分组,并细分四组:无mpMRI无活检、单纯活检、mpMRI±靶向活检、活检联合mpMRI±靶向活检。

主要发现

  • 445例中132例(30%)停止主动监测并接受治疗,中位至治疗时间1.55年(IQR 0.71-2.4)。
  • 最常见治疗触发为mpMRI及靶向活检后前列腺癌升级(43/132例,29%)。
  • 单纯活检组与mpMRI±靶向活检组至治疗时间无显著差异(中位1.9 vs 1.33年,P=0.747)。
  • 仅接受重复活检者中,mpMRI后靶向活检组停止主动监测比例高于单纯活检组(29/66[44%] vs 32/87[37%],P=0.003)。
  • 无论单纯活检还是靶向活检,平均需一组重复活检触发治疗。

临床怎么用

  • 在主动监测方案中采用mpMRI±靶向活检有助于识别需治疗的临床显著前列腺癌患者。
  • mpMRI±靶向活检作为主动监测的一部分,代表主动监测方案肿瘤学安全性的显著进步。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine whether replacement of protocol-driven repeat prostate biopsy (PB) with multiparametric magnetic resonance imaging (mpMRI) ± repeat targeted prostate biopsy (TB) when evaluating men on active surveillance (AS) for low-volume, low- to intermediate-risk prostate cancer (PCa) altered the likelihood of or time to treatment, or reduced the number of repeat biopsies required to trigger treatment. PATIENTS AND METHODS: A total of 445 patients underwent AS in the period 2010-2016 at our institution, with a median (interquartile range [IQR]) follow-up of 2.4 (1.2-3.7) years. Up to 2014, patients followed a 'pre-2014' AS protocol, which incorporated PB, and subsequently, according to the 2014 National Institute for Health and Care Excellence (NICE) guidelines, patients followed a '2014-present' AS protocol that included mpMRI. We identified four groups of patients within the cohort: 'no mpMRI and no PB'; 'PB alone'; 'mpMRI ± TB'; and 'PB and mpMRI ± TB'. Kaplan-Meier plots and log-rank tests were used to compare groups. RESULTS: Of 445 patients, 132 (30%) discontinued AS and underwent treatment intervention, with a median (IQR) time to treatment of 1.55 (0.71-2.4) years. The commonest trigger for treatment was PCa upgrading after mpMRI and TB (43/132 patients, 29%). No significant difference was observed in the time at which patients receiving a PB alone or receiving mpMRI ± TB discontinued AS to undergo treatment (median 1.9 vs 1.33 years; P = 0.747). Considering only those patients who underwent repeat biopsy, a greater proportion of patients receiving TB after mpMRI discontinued AS compared with those receiving PB alone (29/66 [44%] vs 32/87 [37%]; P = 0.003). On average, a single set of repeat biopsies was needed to trigger treatment regardless of whether this was a PB or TB. CONCLUSIONS: Replacing a systematic PB with mpMRI ±TB as part of an AS protocol increased the likelihood of re-classifying patients on AS and identifying men with clinically significant disease requiring treatment. mpMRI ±TB as part of AS thereby represents a significant advance in the oncological safety of the AS protocol.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Bryant RJ, Yang B, Philippou Y, et al. Does the introduction of prostate multiparametric magnetic resonance imaging into the active surveillance protocol for localized prostate cancer improve patient re-classification? BJU Int. 2018. PMID: 29645347. doi:10.1111/bju.14248

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。